Related Experiment Video
Updated: Mar 20, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Recent Progress in Triple Negative Breast Cancer Research
Fatima Zahra Mouh1, Mohammed El Mzibri, Meriem Slaoui
1Equipe deRecherche ONCOGYMA, University of Mohamed V, Faculty of Medicine and Pharmacy of Rabat Morocco
Abstract:
Triple-negative breast cancer (TNBC) is defined as a type of breast carcinoma that is negative for expression of oestrogene and progesterone hormone receptors (ER, PR) and HER2. This form of breast cancer is marked by its aggressiveness, low survival rate and lack of specific therapies. Recently, important molecular characteristics of TNBC have been highlighted and led to the identification of some biomarkers that could be used in diagnosis, as therapeutic targets or to assess the prognosis. In this review, we summarize recent progress in TNBC research focusing on the genetic and epigenetic alterations of TNBC and the potential use of these biomarkers in the targeted therapy for better management of TNBC.
Insights
Triple-negative breast cancer (TNBC) is aggressive and lacks targeted therapies. Research highlights genetic and epigenetic biomarkers for improved diagnosis, prognosis, and targeted treatment strategies for TNBC.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Triple-negative breast cancer (TNBC) lacks estrogen/progesterone receptors (ER, PR) and HER2 expression.
- TNBC is characterized by high aggressiveness, poor survival rates, and limited targeted therapeutic options.
- Recent advancements have identified key molecular characteristics and potential biomarkers for TNBC.
Purpose of the Study:
- To review recent progress in triple-negative breast cancer research.
- To focus on genetic and epigenetic alterations in TNBC.
- To explore the utility of identified biomarkers in targeted therapy and patient management.
Main Methods:
- Literature review of recent TNBC research.
- Analysis of genetic and epigenetic alterations.
- Evaluation of biomarker potential for diagnosis, prognosis, and therapy.
Main Results:
- Identification of significant genetic and epigenetic alterations in TNBC.
- Discovery of potential biomarkers for TNBC diagnosis and prognosis.
- Emerging strategies for targeted therapy based on molecular characteristics.
Conclusions:
- Genetic and epigenetic alterations are crucial in TNBC pathogenesis.
- Biomarkers hold promise for personalized medicine approaches in TNBC.
- Targeted therapies informed by molecular insights can improve TNBC management.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...